Diabetic Peripheral Neuropathic Pain
The Diabetic Peripheral Neuropathic Pain pipeline: 16 tracked drugs, 4 approved for this indication.
4 approved / phase 43 Phase 37 Phase 21 Phase 11 preclinical / unstaged
Compare the share prices of listed companies in Diabetic Peripheral Neuropathic Pain →
Total attributable cost
$101.0B
$16,588/patient
Drug spend
Not yet sourced
All severities · US
The Diabetic Peripheral Neuropathic Pain pipeline
Key trial results for every approved and late-stage drug: Diabetic Peripheral Neuropathic Pain results by drug.